Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in development of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Terns Pharmaceuticals Inc. is based in FOSTER CITY, Calif.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-88.85M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.81 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -28.81% |
| Return on Assets (Trailing 12 Months) | -27.55% |
| Current Ratio (Most Recent Fiscal Quarter) | 30.89 |
| Quick Ratio (Most Recent Fiscal Quarter) | 30.89 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.26 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.12 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.09 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 87.34M |
| Free Float | 86.03M |
| Market Capitalization | $265.50M |
| Average Volume (Last 20 Days) | 0.99M |
| Beta (Past 60 Months) | -0.16 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.26% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |